NASDAQ : BCAX
Bicara Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 9.13 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 604.16M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 42.79M | 30.51M | 18.77M | 9.27M | 6.34M |
| Research & Development | 159.20M | 125.10M | 63.62M | 30.62M | 31.31M |
| Operating Expenses | 201.99M | 155.60M | 82.39M | 39.89M | 37.66M |
| Operating Income | -201.99M | -155.60M | -82.39M | -39.89M | -37.66M |
| Interest Expense | -112.00K | ||||
| Interest & Investment Income | 16.83M | 17.87M | 14.58M | 1.31M | 4.00K |
| Other Non Operating Income (Expenses) | -13.40M | -80.00K | |||
| Pretax Income | -185.16M | -137.73M | -67.81M | -51.98M | -37.84M |
| Income Tax Expense | 208.00K | 217.00K | 187.00K | 5.00K | 1.00K |
| Net Income | -185.36M | -137.95M | -68.00M | -51.98M | -37.84M |
| Net Income to Common | -185.36M | -137.95M | -68.00M | -51.98M | -37.84M |
| Shares Outstanding (Basic) | 59.61M | 54.68M | 16.81M | 580.11K | 429.08K |
| Shares Outstanding (Diluted) | 59.61M | 54.68M | 16.81M | 580.11K | 429.08K |
| EPS (Basic) | -3.11 | -2.52 | -4.05 | -89.61 | -88.20 |
| EPS (Diluted) | -3.11 | -2.52 | -4.05 | -89.61 | -88.20 |
| Free Cash Flow | -135.25M | -107.11M | -74.82M | -46.21M | -32.27M |
| Free Cash Flow Per Share | -2.27 | -1.96 | -4.45 | -79.66 | -75.20 |
| EBITDA | -201.83M | -155.50M | -82.33M | -39.87M | -37.65M |
| D&A For EBITDA | 155.00K | 105.00K | 56.00K | 19.00K | 10.00K |
| EBIT | -201.99M | -155.60M | -82.39M | -39.89M | -37.66M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 96.60M | 96.69M | 489.71M | 230.44M | 4.16M |
| Short-Term Investments | 400.66M | 318.12M | |||
| Cash & Short-Term Investments | 497.26M | 414.80M | 489.71M | 230.44M | 4.16M |
| Receivables | 100.00K | 68.00K | |||
| Prepaid Expenses | 6.56M | 7.25M | 12.82M | 533.00K | 758.00K |
| Total Current Assets | 503.82M | 422.05M | 502.53M | 231.07M | 4.98M |
| Property, Plant & Equipment | 1.51M | 2.03M | 845.00K | 815.00K | 636.00K |
| Other Long-Term Assets | 6.91M | 6.91M | 6.62M | 1.99M | 944.00K |
| Total Assets | 512.24M | 430.99M | 510.00M | 233.98M | 6.70M |
| Accounts Payable | 8.46M | 5.51M | 3.89M | 3.19M | 5.14M |
| Accrued Expenses | 33.85M | 22.32M | 13.49M | 11.61M | 18.76M |
| Current Portion of Leases | 1.16M | 1.12M | 607.00K | 285.00K | |
| Total Current Liabilities | 43.48M | 28.95M | 17.99M | 15.09M | 23.90M |
| Long-Term Leases | 593.00K | 131.00K | 372.00K | ||
| Other Long-Term Liabilities | 17.00K | 85.00K | |||
| Total Liabilities | 43.48M | 29.54M | 18.12M | 15.47M | 23.98M |
| Common Stock | 8.00K | 7.00K | 7.00K | 2.00K | 2.00K |
| Additional Paid-In Capital | 939.94M | 760.17M | 712.88M | 4.25M | 2.23M |
| Retained Earnings | -470.61M | -358.97M | -221.02M | -153.02M | -101.04M |
| Comprehensive Income & Other | -567.00K | 243.00K | |||
| Total Common Equity | 468.77M | 401.45M | 491.88M | -148.77M | -98.80M |
| Shareholders' Equity | 468.77M | 401.45M | 491.88M | 218.51M | -17.28M |
| Total Liabilities & Equity | 512.24M | 430.99M | 510.00M | 233.98M | 6.70M |
| Total Debt | 1.16M | 1.71M | 738.00K | 657.00K | |
| Net Cash (Debt) | 496.10M | 413.09M | 488.97M | 229.78M | 4.16M |
| Net Cash Per Share | 8.32 | 7.56 | 29.10 | 396.10 | 9.69 |
| Filing Date Shares Outstanding | 66.17M | 65.47M | 54.52M | 34.26M | 429.08K |
| Total Common Shares Outstanding | 65.93M | 54.44M | 54.44M | 640.84K | 429.08K |
| Working Capital | 460.35M | 393.10M | 484.54M | 215.99M | -18.91M |
| Book Value Per Share | 7.11 | 7.37 | 9.04 | -232.15 | -230.26 |
| Tangible Book Value | 468.77M | 401.45M | 491.88M | -148.77M | -98.80M |
| Tangible Book Value Per Share | 7.11 | 7.37 | 9.04 | -232.15 | -230.26 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -185.36M | -137.95M | -68.00M | -51.98M | -37.84M |
| Depreciation & Amortization | 155.00K | 105.00K | 56.00K | 19.00K | 10.00K |
| Asset Writedown & Restructuring Costs | 568.00K | ||||
| Loss (Gain) From Sale of Investments | 876.00K | 301.00K | |||
| Stock-Based Compensation | 22.16M | 15.01M | 7.40M | 1.90M | 810.00K |
| Other Operating Activities | 1.10M | 895.00K | -77.00K | 13.49M | |
| Change in Accounts Payable | 26.16M | 10.46M | 2.64M | -8.66M | 5.87M |
| Change in Other Net Operating Assets | 71.00K | 4.35M | -16.77M | -961.00K | -922.00K |
| Operating Cash Flow | -134.85M | -106.83M | -74.75M | -45.63M | -32.08M |
| Capital Expenditures | -400.00K | -280.00K | -71.00K | -586.00K | -192.00K |
| Sale of Property, Plant & Equipment | 62.00K | ||||
| Investment in Securities | -402.10M | -318.17M | |||
| Investing Cash Flow | -402.50M | -318.45M | -9.00K | -586.00K | -192.00K |
| Issuance of Common Stock | 197.34M | 32.26M | 334.03M | 149.00K | 160.00K |
| Financing Cash Flow | 197.34M | 32.26M | 334.03M | 272.50M | 31.70M |
| Net Cash Flow | -340.01M | -393.03M | 259.27M | 226.28M | -573.00K |
| Free Cash Flow | -135.25M | -107.11M | -74.82M | -46.21M | -32.27M |
| Free Cash Flow Per Share | -2.27 | -1.96 | -4.45 | -79.66 | -75.20 |
| Levered Free Cash Flow | -76.95M | -66.40M | -53.72M | -32.50M | |
| Unlevered Free Cash Flow | -76.95M | -66.40M | -53.72M | -32.50M | |
| Cash Income Tax Paid | 31.00K | 1.00K | |||
| Change in Working Capital | 26.23M | 14.81M | -14.13M | -9.62M | 4.95M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 533.68M | 921.98M | 947.92M | ||
| Enterprise Value | 37.59M | 633.79M | 427.61M | ||
| Last Close Price | 9.13 | 16.83 | 17.42 | ||
| PB Ratio | 1.28 | 2.30 | 1.93 | ||
| P/TBV Ratio | 1.14 | 2.30 | 1.93 | ||
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Debt / Equity Ratio | -1.06 | -1.03 | -0.99 | -1.05 | 0.24 |
| Net Debt / EBITDA Ratio | 2.46 | 2.66 | 5.94 | 5.76 | 0.11 |
| Net Debt / FCF Ratio | 3.67 | 3.86 | 6.54 | 4.97 | 0.13 |
| Quick Ratio | 11.44 | 14.33 | 27.22 | 15.28 | 0.17 |
| Current Ratio | 11.59 | 14.58 | 27.93 | 15.32 | 0.21 |
| Return on Equity (ROE) | -41.01% | -30.88% | -19.14% | -51.67% | |
| Return on Assets (ROA) | -26.14% | -20.67% | -13.84% | -20.72% | |
| Return on Capital Employed (ROCE) | -43.10% | -38.70% | -16.70% | -18.20% | 219.00% |
| Earnings Yield | -38.56% | -14.96% | -7.17% | ||
| FCF Yield | -25.30% | -11.62% | -7.89% | ||
| Buyback Yield / Dilution | -36.51% | -225.35% | -2,796.96% | -35.20% |